UnknownNot Applicable

Abdominal or Transanal TME for Rectal Cancer Therapy

Switzerland300 participantsStarted 2012-01-01

Plain-language summary

This study assessed whether transanal TME in patients with rectal cancer is superior to open, laparoscopic, and robotic TME (abdominal TME (abTME)) regarding oncological outcome, postoperative morbidity and 90-day mortality.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * all patients receiving elective total mesorectal excision Exclusion Criteria: * diagnosis other than rectal cancer * partial mesorectal excision * discontinuity resection (no anastomosis) * incomplete Staging * metastatic cancer * lack of follow-up * decline of a retrospective data Analysis * age under 18 years

What they're measuring

Overall survival

Timeframe: 60 months

cancer-specific survival

Timeframe: 60 months

disease-specific survival

Timeframe: 60 months

Trial details

NCT IDNCT04969107

SponsorCantonal Hospital of St. Gallen

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-12-31

Contact for this trial

Lukas Marti, Dr. med.

+41 71 494 13 39 lukas.marti@kssg.ch

View on ClinicalTrials.gov More Survival trials